Diagnostic methods for liver disorders
AssigneeMeso Scale Technologies, LLC.
InventorsEli N. Glezer, Anu Mathew, Martin Stengelin, Mingyue Wang
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of diagnosing a liver disorder in a patient, as well as methods of monitoring the progression of a liver disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a chemotherapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.
Claims57
A method for diagnosing HCC in a patient, said method comprising
- (a) measuring a level of a first biomarker in a test sample obtained from a patient, wherein said first biomarker is selected from the group consisting of CEA, CA 125, CA 19-9;
- and
- (b) diagnosing from said measuring step the presence or absence of HCC in said patient.
A method for monitoring the progression of HCC in a patient diagnosed with HCC, said method comprising
- (a) measuring the levels of a first biomarker in a plurality of samples obtained, at different times, from said patient, wherein said first biomarker is selected from the group consisting of CEA, CA 125, CA 19-9;
- and
- (b) determining from said levels of said first biomarker the progression or efficacy of treatment of the HCC.
A method for diagnosing cirrhosis in a patient suspected of having cirrhosis, said method comprising
- (a) measuring a level of a first biomarker in a test sample obtained from a patient, wherein said first biomarker is selected from the group consisting of CEA, CA 125, CA 19-9;
- and
- (b) diagnosing from said measuring step the presence or absence of cirrhosis in said patient.
A method for monitoring the progression of cirrhosis in a patient diagnosed with cirrhosis, said method comprising
- (a) measuring the level(s) of a first biomarker in a plurality of samples obtained, at different times, from said patient, wherein said first biomarker is selected from the group consisting of CEA, CA 125, CA 19-9;
- and
- (b) determining from said level(s) of said first biomarker the progression or efficacy of treatment of cirrhosis.
Dependencies are inferred from the claim text.